A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Chronic PancreatitisExocrine Pancreatic Insufficiency
Interventions
DRUG

Placebo

Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).

DRUG

EUR-1008 (APT-1008) High Dose

EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.

DRUG

EUR-1008 (APT-1008) Low Dose

EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.

Trial Locations (18)

20089

Istituto Clinico Humanitas - Universita' Di Milano Via Manzoni, Rozzano

32127

Advanced Medical Research Center, Port Orange

32610

University of Florida, General Clinical Research Center, Gainesville

40202

University of Louisville, Carmichael Building, Louisville

40536

University of Kentucky, Medical Center, Department of Gastroenterology, Lexington

52242

University of Iowa Hospitals and Clinics, Iowa Ctiy

60141

Veterans Affairs Edward Jr. Hines Hospital, Building #1, Hines

61039

Department of Liver and Gastrointestinal Tract Disease Institute of Therapy named after L.T. Maylaya of Academy of Medical Sciences of the Ukraine, Kharkiv

65212

University of Missouri Health Care, Columbia

72211

Woodland International Research Group, Little Rock

83017

Department of Internal Medicine No 2 of Donetsk State University named after M. Gorkly, City Clinical Hospital No 3, Donetsk

90015

HealthCare Partners Medical Group, Los Angeles

95017

Department of Therapy and Family Medicine of the Facility of Post graduate Education of Crimea State Medical University named after S.I. Georglyevskyy Republic Clinical Hospital named after M.O. Semashko, Simferopol

9-40138

Dipartmento di Malattie dell' apparato digerente e Medicina Interna- Unita Operativa di MedicinaInterna Corinaldesi Azienda Ospedaliero- Universitaria Policlinico Sant'Orsola Malpighi Via Massarenti, Massarenti

8 00168

Istituto di Clinica Chirurgica (Ensoscopia Digestive Chirurgica) Policlinico Gemelli-Universita Cattolica del Sacro Cuore, Largo Agostino Gemelli

10 37134

Centro Richerche Cliniche di Verona, Le Ludovico Scuro

01030

Department of Faculty Therapy No 1 with the Course of Postgraduate Training of Physicians for Gastroenterology and Endoscopy, National Medical University named after O.O. Bogomolets, City Hospital No 18, Kyiv

01133

General Therapy Clinic, Military Clinical Hospital of Ministry of Defense of Ukraine 18, Kyiv

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT00788593 - A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) | Biotech Hunter | Biotech Hunter